Design and application of hybrid cyclic-linear peptide-doxorubicin conjugates as a strategy to overcome doxorubicin resistance and toxicity

Doxorubicin (Dox) is used for breast cancer, leukemia, and lymphoma treatment as an effective chemotherapeutic agent. However, Dox use is restricted due to inherent and acquired resistance and an 8-fold increase in the risk of potentially fatal cardiotoxicity. Hybrid cyclic-linear peptide [R5K]W(7)A and linear peptide R(5)KW(7)A were conjugated with Dox through a glutarate linker to afford [R5K]W(7)A-Dox and R(5)KW(7)A-Dox conjugates to generate Dox derivatives. Alternatively, [R5K]W7C was conjugated with Dox via a disulfide linker to generate [R5K]W7C-S-S-Dox conjugate, where S-S is a disulfide bond. Comparative antiproliferative assays between conjugates [R5K]W(7)A-Dox, [R5K]W7C-S-S-Dox, linear R(5)KW(7)A-Dox, the corresponding physical mixtures of the peptides, and Dox were performed in normal and cancer cells. [R5K]W(7)A-Dox conjugate was 2-fold more efficient than R(5)KW(7)A-Dox, and [R5K]W7C-S -S-Dox conjugates in inhibiting the cell proliferation of human leukemia cells (CCRF-CEM). Therefore, hybrid cyclic-linear [R5K]W(7)A-Dox conjugate was selected for further studies and inhibited the cell viability of CCRF-CEM (84%), ovarian adenocarcinoma (SK-OV-3, 39%), and gastric carcinoma (AGS, 73%) at a concentration of 5 tiM after 72 h of incubation, which was comparable to Dox (5 mu M) efficacy (CCRFCEM (85%), SK-OV-3 (33%), and AGS (87%)). While [R5K]W(7)A-Dox had a significant effect on the viability of cancer cells, it exhibited minimal cytotoxicity to normal kidney (LLC-PK1, 5-7%) and heart cells (H9C2, <9%) at concentrations of 5-10 tM (compared to free Dox at 5 tM that reduced the viability of kidney and heart cells by 85% and 44%, respectively). The fluorescence microscopy images were consistent with the cytotoxicity studies, indicating minimal uptake of the cyclic-linear [R5K]W(7)A-Dox (5 mu M) in H9C2 cells. In comparison, Dox (5 mu M) showed significant uptake, reduced cell viability, and changed the morphology of the cells after 24 h. [R5K]W(7)A-Dox showed 16-fold and 9.5-fold higher activity against Dox-resistant cells MDA231R and MES-SA/MX2 (lethal dose for 50% cell death or LC50 of 2.3 and 4.3 mu M, respectively) compared to free Dox (LC50 of 36-41 mu M, respectively). These data, along with the results obtained from the cell viability tests, indicate comparable efficiency of [R5K]W(7)A-Dox to free Dox in leukemia, ovarian, and gastric cancer cells, significantly reduced toxicity in normal kidney LLC-PK1 and heart H9C2 cells, and significantly higher efficiency in Dox-resistant cells. A number of endocytosis inhibitors did not affect the cellular uptake of [R5K]W(7)A-Dox. (C) 2021 Elsevier Masson SAS. All rights reserved.

Automated summary

The hybrid cyclic-linear [R5K]W(7)A-Dox conjugate showed significant efficacy in inhibiting cancer cell proliferation with minimal toxicity to normal cells, compared to free Dox. It also exhibited higher efficiency in Dox-resistant cells when compared to free Dox.